Fig. 5
From: Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
Tofacitinib effects on serum levels of VEGF and Ang-2 in vivo model of experimental arthritis. A ELISA assay of VEGF. The serum levels of VEGF in CIA mice were significantly increased, when compared to control mice. Tofacitinib prevented the increase of serum levels of VEGF, when compared to CIA mice untreated with tofacitinib (*p ≤ 0.04). B The serum ELISA assay of Ang-2. The serum levels of Ang-2 in CIA mice were significantly increased, when compared to control mice. Tofacitinib prevented the increase of serum levels of Ang-2, when compared to CIA mice untreated with tofacitinib (*p = 0.01; **p = 0.002; ***p ≤ 0.0001)